Takeda provides update on TOURMALINE-MM2 phase III trial of ixazomib + lenalidomide + dexamethasone to treat transplantation ineligible multiple myeloma patients.
Related news and insights
Legend Biotech Corp announced that CARTITUDE-4, the Phase III study evaluating Carvykti (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint of showing a statistically significant improvement in progression-free survival (PFS) compared to standard therapy at the study’s first pre-specified interim analysis.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of JNJ 64407564 (talquetamab) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM)
Pfizer announced 10.4 month follow-up data from the pivotal Phase II MagnetisMM-3 clinical trial suggesting elranatamab, a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), is efficacious and has a manageable safety profile in patients with relapsed or refractory multiple myeloma (RRMM) in a heavily pretreated population, who have received at least three classes of prior therapies including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody (i.e. triple-class refractory or exposed).